AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deucravacitinib
Description: Deucravacitinib will be administered orally.
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally for daily for 28 days
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.
Study NCT06220604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.
Study NCT04667663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1,800mg) will be administered by a subcutaneous injection once every week for 2 cycles (Cycles 1-2), then once every 2 weeks for 4 cycles (Cycles 3-6), and following this (Cycle 7 onwards), patients will receive daratumumab once every four weeks.
Study NCT04667663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered PO at 50mg daily for all cohorts in the study.
Study NCT04667663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered PO on days 1-21 of each 28 day cycle. The dose will be specified by the dose level to which the patient has been enrolled.
Study NCT04667663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered PO at 40mg on days 1, 8, 15 and 22 of each 28 day cycle.
Study NCT06122285 — intervention group
Intervention type: DRUG
Intervention: Bulevirtide
Description: dose of 2 mg/day subcutaneously
Study NCT04585438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac Potassium
Description: The drug will be used as a transparent disc applied to the mucosa
Study NCT04585438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: The drug will be used as a transparent disc applied to the mucosa
Study NCT05856214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-Based Violence Prevention education(CBVPE)
Description: Couples in the intervention group will receive training on violence against women including intimate partner violence, types, and consequences of intimate partner violence during pregnancy, managing triggers of intimate partner violence, healthy relationships, the role of male partners during pregnancy, and couples communication and problem-solving skills. Training will be provided every fourth week by trained health extension workers for consecutive six months.
Study NCT05535387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamilyNet smart speaker/mobile application
Description: In a 4- to 6-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
Study NCT05073042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning exercise goal
Description: Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 AM and 10 AM each day.
Study NCT05073042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evening exercise goal
Description: Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes between 5 PM and 10 PM each day.
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9 cis retinoic acid
Description: 9 cis retinoic acid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
Study NCT05073042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time of choice exercise goal
Description: Participants will be instructed to walk at a moderate intensity for at least 15 continuous minutes at a time of their choice each day. This time can change day-to-day.
Study NCT06684808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitness
Description: The Fitness group engaged in active breaks aimed at improving cardiovascular efficiency. These breaks were designed to provide moderate to vigorous physical activity, incorporating both strength and aerobic exercises such as squats, jumping jacks, lunges, and running in place. Children were instructed to imitate the teacher's movements.
Study NCT06684808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative
Description: The Creative group participated in active breaks that combined cognitive-creative and physical demands, incorporating activities like improvisations, dramatizations of events or short stories, simulation, and imitation games. These activities aimed to stimulate the creative process and enhance emotional expression within environmental constraints. Constraints, set by the teacher-such as specific rules, partner positioning, or speed of execution-limited movement options, encouraging students to explore new solutions to complete each task.
Study NCT06684808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: The Combined group took active breaks by combining the Fitness protocol in the first break and the Creative protocol in the second.
Study NCT06684808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Regular physical activity at school during the weeks.
Study NCT06685614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic bracket bonding
Description: compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models
Study NCT06685614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic bracket bonding
Description: compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients will be given 10mg Tamoxifen twice a day. Treatment will last 28 days
Study NCT05016349 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Patients will receive the approved standard therapy tamoxifen
Study NCT06528665 — intervention group
Intervention type: DRUG
Intervention: ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
Description: ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned.
Study NCT06685744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation_TRsA
Description: Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach.
Study NCT06685744 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational treatment
Description: Home rehabilitation indications according to a conventional approach, customized according to the disease.
Study NCT06685744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation_TRcA
Description: Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: a combination of exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach together with exercises aimed at recovering muscle strength (resistance) and improving endurance (endurance) using an Impairment-oriented approach.
Study NCT06627309 — intervention group
Intervention type: DRUG
Intervention: Dara IV
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Study NCT06627309 — intervention group
Intervention type: DRUG
Intervention: Bortezomib (drug)
Description: Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles
Study NCT06627309 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
Study NCT05535257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential Compression Device
Description: Calf size lower extremity sequential compression device sleeve will be placed on the weak upper extremity blow the cubital fossa and may include the hand if necessary. The device will inflate and deflate.
Study NCT06328582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.
Study NCT06328582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.
Study NCT06328582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture
Description: Acupuncture Technique for Restoring Consciousness:~Main acupoints: Neiguan (bilateral), Renzhong, Sanyinjiao (affected side) Additional acupoints: Fengchi, Wangu, Yifeng (bilateral), and posterior pharyngeal wall needling.~Scalp Acupuncture Method:~Based on the standard treatment lines for scalp acupuncture \[17\], select the anterior oblique line of vertex-temporal region, posterior oblique line of vertex-temporal region, and anterior line of temporal region (bilateral).
Study NCT05083143 — intervention group
Intervention type: BEHAVIORAL
Intervention: COVID-19 pandemic
Description: Patients diagnosed with testicular cancer in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
Study NCT05363709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given by Vein (IV)
Study NCT06627309 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide (CTX)
Description: Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.
Study NCT06627309 — intervention group
Intervention type: DRUG
Intervention: Dara SC
Description: The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
Study NCT06619808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).
Study NCT06447597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15
Study NCT06447597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
Study NCT05250544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: For the adolescents in the control group; As soon as the process starts, the stopwatch will be started, and when the process is finished, it will be stopped. When the PCR Test starts, the crying state of the adolescent will be observed and recorded. After the procedure, the adolescent's fear (Childiren's Fear Scala (CFS)) and pain (Wong Baker FACES) related to the procedure will be evaluated separately by the adolescent, parent and observer and recorded in the form.
Study NCT05690568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: multimodal chiropractic care
Description: functional movement score followed by intervention of multimodal chiropractic care including spinal/extremity manipulation and exercise recommendation
Study NCT05301504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 biEBOV
Description: ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
Study NCT04936997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-COV2 Pfizer Vaccine
Description: Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Study NCT06682689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
Study NCT06682689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation
Description: Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
Study NCT06682195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with Toripalimab
Description: 1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment.
Study NCT06684834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5:2 carbohydrate restriction
Description: Carbohydrate ingestion restricted to \<8% of energy intake on 2 self-selected consecutive days each week over 28-30 days. Ad libitum dietary amount, type and pattern followed on the remaining 5 days each week.
Study NCT06684834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early time-restricted carbohydrate intake
Description: Carbohydrate intake restricted to \<8% of energy intake after 4pm each day for 28 days. Ad libitum dietary amount, type and pattern followed before 4pm.
Study NCT06685575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Foraminotomy Surgery
Description: Endoscopic Foraminotomy Surgery in Stable Lumbar Foraminal Stenosis
Study NCT06685471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screeing test
Description: Simulation-Based Training Program Effect on Pediatric Nurses' Knowledge and Performance Regarding Heel-Prick during Newborn Blood Screening Test
Study NCT06684236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation
Description: electrical stimulation is given through electrodes attached to the skin
Study NCT06684236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrodes attachment
Description: electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
Study NCT06684236 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrodes attachment
Description: electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
Study NCT05498155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Olaparib monotherapy group
Description: Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
Study NCT05498155 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combination therapy with olaparib plus durvalumab
Description: Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
Study NCT06682364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-informed case management for women who use drugs
Description: This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
Study NCT06682364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed case management for women who use drugs
Description: This intervention assesses the adequacy in which components of the gender-specific and trauma-informed intervention function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
Study NCT06682364 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRS Only Intervention
Description: This intervention assesses the adequacy in which components of the gender-specific case management by certified peer recovery specialists function together using a sample of 50 community-recruited CJI women who use opioids illicitly.
Study NCT06685666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional warm-up method specific to handball
Description: The traditional warm-up program specific to handball consists of 6 basic sections: static stretching, aerobic work, dynamic mobility exercises, passes and crosses, shooting on goal and shooting according to position, and lasts 17 minutes in total.